INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2023

INTANGIBLE ASSETS [Abstract]

INTANGIBLE ASSETS

5. INTANGIBLE ASSETS

Intangible assets at December 31, 2023 and 2022 consist of the following:

	December 31, 2023						December 31, 2022
	(In thousands)
	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
Trademark and other intangible rights related to Nabi-HB	$	4,100	$	3,856	$	244	$	4,100	$	3,270	$	830
Internally developed software		210		9		201		-		-		-
Rights to intermediates		907		853		54		907		724		183
	$	5,217	$	4,718	$	499	$	5,007	$	3,994	$	1,013

Under the previous contract manufacturing agreement between ADMA and Biotest, intermediate by-products derived from the manufacture of ASCENIV were property of Biotest. As a result of the acquisition of certain assets from Biotest on June 6, 2017, ADMA obtained the right to these intermediate products, which are being amortized over a period of seven years. The intangible rights to Nabi-HB are also being amortized over a period of seven years. During the year ended December 31, 2023, the Company implemented an internally developed data intelligence and analytics program at a cost of approximately $0.2 million which is being amortized over a period of four years.

Amortization expense related to the Company’s intangible assets for the years ended December 31, 2023, 2022 and 2021 was $0.7 million. Estimated aggregate future aggregate amortization expense is expected to be as follows (in thousands):

2024	$	351
2025		52
2026		52
2027		44